AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
SAN FRANCISCO--Another J.P. Morgan Healthcare Conference is in the books, and biopharma's movers, shakers and up-and-comers have headed back to Boston, Basel and Bangalore. This year, in the shadow of the best market for biotech IPOs since 2000, there's fresh optimism that capital will continue to flow into drug developers' pockets, whether via more market debuts or through the many top-tier VCs putting together new funds.
To no one's surprise, cancer immunotherapies are hogging much of the spotlight, but Intercept's explosive week put NASH near the top of the list of biopharma buzzwords, and a host of promising RNA therapies from companies big and small grabbed some headlines. Through it all, the Fierce team was darting in and out of presentations, one-on-ones and cafe chats in and around Union Square to bring you this, our annual industry barometer.
POPULAR COMMENT THREADS
Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.
Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.
CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.
Catalent has signed a deal to lend its biologics development technology to China's Zhejiang Hisun Pharmaceuticals and help the drugmaker get working on copies of some top-selling drugs.
Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.
From Our Sister Sites
Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.
Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests.